GlassScriptPhysician profile
Adam Scott Clark
NPI 1700431749
$2,430.67
in general payments reported to CMS, 2019-2025
11 companies · $529 in 2025
The $529 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $101 · 2021: $357 · 2022: $462 · 2023: $278 · 2024: $485 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,055.00 | 2020-2025 | Clareon, Hydrus Microstent, Dailies Total1 |
| Biotissue Holdings INC. | $241.60 | 2022-2024 | |
| Dompe US, INC. | $209.77 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $202.53 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $146.47 | 2019-2023 | Cequa |
| Coopervision INC. | $135.93 | 2023-2024 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Bausch & Lomb Americas INC. | $113.73 | 2023 | Miebo |
| Allergan, INC. | $94.85 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $59.90 | 2024-2025 | Xdemvy |
| Abbvie INC. | $45.89 | 2022-2023 | Durysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.